Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) levels in patients with overt and subclinical hyperthyroidism: effects of treatment


EREM C., CİVAN N., COSKUN H., MENTEŞE A., SÜLEYMAN A. K. , ALTAY D. U. , ...More

CLINICAL ENDOCRINOLOGY, vol.84, no.6, pp.919-924, 2016 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 84 Issue: 6
  • Publication Date: 2016
  • Doi Number: 10.1111/cen.12955
  • Journal Name: CLINICAL ENDOCRINOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.919-924

Abstract

Background and ObjectivesSignal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) has been shown to increase in parallel with platelet activation in acute ischaemic and thrombotic diseases. There has been no study evaluating SCUBE1 levels in patients with overt hyperthyroidism (OHyper) and subclinical hyperthyroidism (SHyper), conditions which are known to show impairment of both endothelial and platelet function. This study sought to evaluate SCUBE1 concentrations in patients with SHyper and OHyper, and assessed the effects of antithyroid drug (ATD) therapy on circulating SCUBE1 levels.